MPA is a dubious disease in the field of autoimmune and rheumatic immunity, clinical performance is complex and often involves multiple systemic burdens. Early identification and standardized diagnosis are essential for improving prognosis. Diagnosis of the disease requires a combination of clinical performance, imaging inspection, laboratory examination and pathological activation.
The platform can assist in matching a team of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. Treatment and management of MPA under the MPA microscope requires individual development, usually including multidimensional management, including pharmacotherapy, rehabilitation interventions, regular follow-up, etc. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many autoimmune and rheumatic immune diseases that have previously been difficult to treat have been significantly improved.
Treatment requires close monitoring of therapeutic efficacy and adverse reactions, adapting to timely regimens according to changes in the condition. Multidisciplinary collaboration (MDT) is particularly important for the integrated management of multi-angiovascular MPA under the microscope. 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.